title: Cell-based immunotherapy against gliomas: from bench to bedside.
abstract: Glioblastoma (GBM) comprises 51% of all gliomas and is the most malignant form of brain tumors with a median survival of 18-21 months. Standard-of-care treatment includes maximal surgical resection of the tumor mass in combination with radiation and chemotherapy. However, as the poor survival rate indicates, these treatments have not been effective in preventing disease progression. Cellular immunotherapy is currently being explored as therapeutic approach to treat malignant brain tumors. In this review, we discuss advances in active, passive, and vaccine-based immunotherapeutic strategies for gliomas both at the bench and in the clinic.
authors: Department of Neurology, Experimental Therapeutics and Molecular Imaging Laboratory, Neuroscience Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
authors: M Sarah S
authors: MS
authors: Bovenberg
authors: M Hannah
authors: MH
authors: Degeling
authors: Bakhos A
authors: BA
authors: Tannous
mesh_terms: D064987:Cell- and Tissue-Based Therapy / Q000379:methods*; D005909:Glioblastoma / Q000628:therapy*; D005910:Glioma / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*
references: Ann Oncol. 2009 May;20 Suppl 4:126-8
references: 19454432
references: Cytotherapy. 2009;11(5):653-68
references: 19530029
references: Neuro Oncol. 2012 Mar;14(3):246-55
references: 22319219
references: Cancer Res. 2005 Aug 15;65(16):7194-204
references: 16103070
references: Am J Cancer Res. 2012;2(3):340-56
references: 22679565
references: J Immunol. 2011 Jan 15;186(2):1218-27
references: 21149605
references: Neurochem Res. 2012 Jun;37(6):1192-200
references: 22228201
references: Vaccine. 2010 Apr 26;28(19):3371-8
references: 20197146
references: PLoS One. 2009 Sep 29;4(9):e7218
references: 19787043
references: Clin Cancer Res. 2012 Apr 15;18(8):2199-209
references: 22407828
references: Nature. 2009 Apr 9;458(7239):766-70
references: 19252478
references: Neurosurg Clin N Am. 2010 Jan;21(1):139-57
references: 19944973
references: J Neurooncol. 2011 Nov;105(2):149-57
references: 21479962
references: Eur J Cancer. 2012 May;48(8):1176-84
references: 22464345
references: PLoS Med. 2009 Jan 13;6(1):e10
references: 19143470
references: Cancer Res. 2004 Dec 15;64(24):9160-6
references: 15604287
references: Neuro Oncol. 2010 Nov;12(11):1113-25
references: 20667896
references: N Engl J Med. 2011 Aug 25;365(8):725-33
references: 21830940
references: Mol Immunol. 2012 Aug;52(1):30-7
references: 22580403
references: Trends Endocrinol Metab. 2012 Jun;23(6):278-85
references: 22537825
references: Nat Rev Immunol. 2007 Oct;7(10):790-802
references: 17853902
references: Nat Med. 2008 Nov;14(11):1264-70
references: 18978797
references: Methods Mol Biol. 2012;879:351-66
references: 22610570
references: Transplant Proc. 1979 Mar;11(1):182-8
references: 377628
references: J Neurosurg. 1988 Feb;68(2):259-65
references: 3276837
references: Cytotherapy. 2009;11(8):1076-83
references: 19929470
references: Neoplasia. 2010 Sep;12(9):675-84
references: 20824044
references: Sci Transl Med. 2011 Aug 10;3(95):95ra73
references: 21832238
references: J Transl Med. 2012 Mar 15;10:48
references: 22420641
references: Blood. 2011 Nov 3;118(18):4817-28
references: 21849486
references: J Clin Neurosci. 2011 Aug;18(8):1048-54
references: 21715171
references: Clin Plast Surg. 2012 Jan;39(1):65-7
references: 22099849
references: J Immunother. 2012 Feb-Mar;35(2):159-68
references: 22306904
references: Bull Cancer. 2007 Sep;94(9):817-22
references: 17878102
references: Neurosurg Focus. 2000 Dec 15;9(6):e9
references: 16817692
references: J Neurosurg. 2010 Aug;113(2):270-9
references: 19895199
references: Expert Opin Drug Discov. 2011 Dec;6(12):1271-83
references: 22647066
references: Mt Sinai J Med. 2010 Nov-Dec;77(6):655-66
references: 21105127
references: Clin Cancer Res. 2011 Jul 15;17(14):4705-18
references: 21632862
references: Lancet Oncol. 2009 May;10(5):459-66
references: 19269895
references: J Clin Oncol. 2010 Oct 20;28(30):4601-8
references: 20855843
references: Yeast. 2010 Nov;27(11):919-31
references: 20672253
references: Cancer. 2012 Nov 15;118(22):5608-13
references: 22569786
references: Melanoma Res. 2010 Aug;20(4):280-92
references: 20375743
references: J Clin Oncol. 2001 Apr 15;19(8):2189-200
references: 11304771
references: J Immunol. 2010 Oct 15;185(8):4793-803
references: 20855883
references: Expert Opin Biol Ther. 2012 Jun;12(6):673-84
references: 22500889
references: Methods Mol Biol. 2010;651:119-30
references: 20686964
references: Nat Biotechnol. 2013 Jan;31(1):71-5
references: 23242161
references: Neurosurg Clin N Am. 2010 Jan;21(1):17-29
references: 19944963
references: Cancer Res. 2010 Dec 1;70(23):9591-8
references: 21098715
references: J Neurooncol. 2011 Jun;103(2):231-8
references: 20820869
references: Nat Cell Biol. 1999 Oct;1(6):362-8
references: 10559964
references: J Immunother. 2011 May;34(4):382-9
references: 21499132
references: Proc Natl Acad Sci U S A. 2010 Aug 3;107(31):13824-9
references: 20631300
references: Stem Cells. 2009 Aug;27(8):1734-40
references: 19536809
references: Mol Ther. 2011 Dec;19(12):2133-43
references: 21772253
references: Br J Surg. 2012 Apr;99(4):451-3
references: 22287115
references: Haematol Blood Transfus. 1979;23:71-8
references: 44507
references: Curr Opin Neurol. 2011 Dec;24(6):641-7
references: 22027543
references: J Neurooncol. 2011 Sep;104(2):439-48
references: 21221712
references: Methods Mol Biol. 2011;767:87-103
references: 21822869
references: Cancer Invest. 2004;22(4):537-44
references: 15565811
references: N Engl J Med. 2005 Mar 10;352(10):987-96
references: 15758009
references: Clin Cancer Res. 2010 Apr 15;16(8):2443-9
references: 20371685
references: Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35
references: 17855649
references: Clin Cancer Res. 2010 Jan 15;16(2):474-85
references: 20068073